Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atea Pharmaceuticals Inc AVIR

Healthcare
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is... see more

Recent & Breaking News (NDAQ:AVIR)

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

GlobeNewswire February 23, 2023

Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

GlobeNewswire February 21, 2023

Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections

GlobeNewswire February 15, 2023

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

GlobeNewswire February 7, 2023

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

GlobeNewswire January 9, 2023

Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

GlobeNewswire November 29, 2022

Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 22, 2022

Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 8, 2022

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 7, 2022

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

GlobeNewswire November 3, 2022

Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022

GlobeNewswire October 31, 2022

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

GlobeNewswire September 26, 2022

Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

GlobeNewswire September 13, 2022

Atea Pharmaceuticals Announces Upcoming Investor Events

GlobeNewswire September 7, 2022

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 8, 2022

Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022

GlobeNewswire August 1, 2022

Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference

GlobeNewswire July 11, 2022

Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

GlobeNewswire June 1, 2022

Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 10, 2022